ClinicalTrials.gg
CompletedNCT06264674TRECOSUpdated Sep 10, 2026

Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

A Phase 3 interventional study of CHF5993 200/6/12.5 μg pMDI HFA-152a and Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 118 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
827
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Enrollment
6th of 66
827 · median 97
Started
2023
with 4 others
Phase 3
24 of 81
2 open now
Registered
69th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 6th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2023, is one of 24 in phase 3, and was the 69th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The CLI-05993AB6-03 Study is an interventional study designed to investigate the safety and efficacy of a new low global warming potential propellant (HFA-152a) compared to the currently approved one (HFA-134a) in the medication (CHF5993) in patients with moderate to severe asthma

Read the detailed description

Outpatients attending the hospital clinics/study centers will be recruited. Moderate to severe controlled asthma adult subjects will be recruited. A total of 513 subjects will be randomised. The whole study will last approximately 16 weeks for each subject.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject's written obtained prior to any study related procedure;
  • Male and female adults aged ≥ 18 and ≤ 75;
  • (BMI) within the range of 18.0 to 35.0 kg/m2 inclusive;
  • Non-smokers or ex-smokers who smoked \< 10 pack-years (pack-years = the number of cigarette packs per day x the number of years) and stopped smoking > 1 year (6 months for e-cigarettes) prior to screening;
  • Diagnosis of asthma: physician-diagnosed asthma for at least
  • 6 months and with diagnosis before the age of 50 years;
  • Stable asthma therapy: a stable treatment with medium/high doses of inhaled (ICS) + long-acting β-agonist (LABA) + long-acting muscarinic antagonist (LAMA) (fixed or free combination) or medium/high doses of ICS+LABA (fixed or free combination) for at least 4 weeks before screening (medium and high-dose ICS defined as BDP non-extrafine > 500-1000 μg and > 1000 μg respectively, or estimated clinical comparable dose).
  • Subjects must have a cooperative attitude and the ability to be trained to use correctly the pMDI inhalers and e-Diary, to be able to read/write, to be able to perform the required outcomes measurements (e.g., technically acceptable spirometry, e-Diary completion) and the ability to understand the risks involved.

Exclusion criteria

Exclusion Criteria:

  • History of near fatal asthma, hospitalisation for asthma in intensive care unit which in the judgement of the Investigator may place the subject at undue risk, emergency room access for asthma in the previous 6 months before enrolment;
  • Asthma exacerbation requiring systemic (SCS) or emergency room admission or hospitalisation within 4 weeks prior to study entry and/or during the run-in period (to be checked again prior to randomisation);
  • Non-permanent asthma: exercise-induced, seasonal asthma (as the only asthma-related diagnosis) not requiring daily asthma control medecine
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
827 participants (actual)

Study arms

  • Experimental
    Inhaler CHF5993 200/6/12.5 μg pMDI HFA-152a

    Active ingredients: BDP/FF/GB 200/6/12.5 μg per actuation; Excipients: HFA-152a propellant.

    Drug: CHF5993 200/6/12.5 μg pMDI HFA-152a

  • Active comparator
    Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

    Active ingredients: BDP/FF/GB 200/6/12.5 μg per actuation; Excipients: HFA-134a propellant.

    Drug: Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

Interventions

  • DrugCHF5993 200/6/12.5 μg pMDI HFA-152a

    Pressurised Metered Dose Inhaler-2 inhalations twice daily

    Also known as: HFA-152a propellant

  • DrugInhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

    Pressurised Metered Dose Inhaler-2 inhalations twice daily

    Also known as: HFA-134a propellant

06

What researchers measure

Primary outcomes

  1. Relative change from pre-dose Forced Expiratory Volume in one second with (FEV1) (Safety Assessment to evaluate of the potential bronchoconstriction of the study treatment)

    Relative change from pre-dose in FEV1 at the 10 min post-dose timepoint

    Time frame: Day 1

Secondary outcomes

  1. To complete the evaluation of FEV1 and the potential for bronchoconstriction of the study treatment (relative change from pre-dose FEV1)

    Relative change from pre-dose in FEV1 at all the post dose timepoints

    Time frame: Day 1, Day 7, Week 4, Week 12

  2. To complete the evaluation of FEV1 and the potential for bronchoconstriction of the study treatment (absolute change from pre-dose FEV1)

    Absolute change from pre-dose in FEV1 at all post-dose timepoints

    Time frame: Day 1, Day 7, Week 4, Week 12

  3. To complete the evaluation of FEV1 and the potential for bronchoconstriction of the study treatment (number and percentage of subjects with a relative decrease from pre-dose in FEV1)

    Calculation of number and percentage of subjects with a relative decrease from pre-dose in FEV1 at each post-dose timpoint and at any post -dose timepoint \> 15%

    Time frame: Day 1, Day 7, Week 4, Week 12

  4. To complete the evaluation of FEV1 and the potential for bronchoconstriction of the study treatment (Absolute and relative changes from baseline in pre-dose FEV1)

    Absolute and relative changes from baseline in pre-dose FEV1 at all clinical visits

    Time frame: Day 1, Day 7, Week 4, Week 12

  5. To complete the evaluation of FEV1 and the potential for bronchoconstriction of the study treatment (Change from pre-dose in FEV1)

    Change from pre-dose in FEV1 AUC 0-2h

    Time frame: Day 1, Day 7, Week 12

  6. Peak expiratory flow (PEF) change from baseline at each inter-visit period over the entire treatment period

    Change from baseline at each inter-visit period and over the entire treatment period in morning and evening PEF

    Time frame: Inter-visit, over the entire 12 weeks treatment period

  7. Percentage of days without intake of rescue medication.

    Change from baseline at each inter-visit period and over the entire treatment period in the percentage of days without intake of rescue medications

    Time frame: Inter-visit, over the entire 12 weeks treatment period

  8. Change in the average daily use of rescue medication.

    Change from baseline at each inter-visit period and over the entire treatment period in the average daily use of rescue medication (number of inhalations/day)

    Time frame: Inter-visit, over the entire 12 weeks treatment period

  9. Change on the average daily asthma symptoms.

    Change from baseline at each inter-visit period and over the entire treatment period in the average daily symptoms. Patients are asked to complete daily a questionnaire to collect this information and allow their asthma symptoms to be monitored.

    Time frame: Inter-visit, over the entire 12 weeks treatment period

  10. Change from baseline in Asthma Control Questionnaire 7 (ACQ 7) score.

    ACQ 7 is a one week recall questionnaire including 6 questions to be completed by patients on a 7-points scale (0=no impairment, 6= maximum impairment) and 7th point capturing the FEV1 % predicted value (also scoring on a 7-point scale). Questions are equally weighted and the ACQ score is the mean of the 7 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).

    Time frame: At each planned on site study visit, during the entire 12 weeks treatment period.

Other outcomes

  1. To measure the safety and tolerability of CHF5993 pMDI HFA-152a in terms of Adverse Events (AEs) / Adverse Drug Reactions (ADRs).

    Number and percentage of subjects experiencing AEs, number and percentage of subjects experiencing at least one ADR and number and percentage of subjects experiencing at least one Treatment Emergent Adverse Events (TEAEs)

    Time frame: Through study completion, an average of 1 year

  2. To measure the safety and tolerability of CHF5993 pMDI HFA-152a in terms of number of Adverse Events (AEs) of particular interest.

    Number of AEs for each of the following event: cough, dysphonia, paradoxical bronchospasm, hypersensitivity reactions, severe asthma Exacerbations

    Time frame: Through study completion, an average of 1 year

  3. To measure the safety and tolerability of CHF5993 pMDI HFA-152a in terms of incident rate of Adverse Events (AEs) of particular interest.

    Incident rate for each of the following AE of particular interest: cough, dysphonia, paradoxical bronchospasm, hypersensitivity reactions, severe asthma Exacerbations.

    Time frame: Through study completion, an average of 1 year

  4. To measure the safety and tolerability of CHF5993 pMDI HFA-152a in terms of rate ration of Adverse Events (AEs) of particular interest.

    Rate ratio between treatments for each of the following AE of particular interest: cough, dysphonia, paradoxical bronchospasm, hypersensitivity reactions, severe asthma Exacerbations.

    Time frame: Through study completion, an average of 1 year

07

Study locations

118 sites
  • "IPSMCPP-D-R Veleva" EOOD
    Burgas, Bulgaria
  • Medical Center "Zdrave -1"
    Kozloduy, Bulgaria
  • "AIPSMP Yuskyan Aliosman" Ltd
    Momchilgrad, Bulgaria
  • Ambulatory for Specialized Outpatient Medical Care - Individual Practice
    Rousse, 7000, Bulgaria
  • Specialized Hospital For Active Treatment Of Pneumo-Phthisiatric Diseases Dr. Dimitar Gramatikov - Ruse Ltd.
    Rousse, 7002, Bulgaria
  • Specialized Hospital For Active Treatment Of Pneumo-Phthisiatric Diseases Dr. Dimitar Gramatikov
    Rousse, 7002, Bulgaria
  • Multiprofile Hospital For Active Treatment - Shumen AD,
    Shumen, 9700, Bulgaria
  • Diagnostic Consultative Centre 1-
    Sliven, 8801, Bulgaria
  • MHAT Sliven to MMA Sofia
    Sliven, Bulgaria
  • University First Multiprofile Hospital for Active Treatment -Sofia "St. Joan Krastilel" EAD
    Sofia, 1142, Bulgaria
  • Multiprofile Hospital For Active Treatment "Knyaginya Klementina" Sofia EAD,
    Sofia, 1233, Bulgaria
  • Medical Center Hera EOOD, 20 Klisura str., fl. 2,
    Sofia, 1510, Bulgaria
  • Multi-profile Hospital for Active Treatment Zdraveto 2012 Ltd.,
    Sofia, 1618, Bulgaria
  • Diagnostics and Consultation Center Convex EOOD
    Sofia, 1680, Bulgaria
  • "Medical Center Sun i Zdrave"
    Sofia, Bulgaria
  • Medical Center "Syrtuin" Ltd
    Sofia, Bulgaria
  • Medical Center "New Rehabilitation Center" Ltd
    Stara Zagora, 6003, Bulgaria
  • ASMP MC Kissiovi Ltd.
    Varna, 9000, Bulgaria
  • Hornmed, s.r.o
    Brno, 618 00, Czechia
  • Nemocnice Jihlava, Plicní oddělení
    Jihlava, 586 01, Czechia
  • MediTrial s.r.o.
    Jindřichův Hradec, 37701, Czechia
  • Pneumology dpt., Poliklinika Budějovická, MEDICON a.s.
    Prague, 140 00, Czechia
  • Pneumology dpt., Fakultní Thomayerova nemocnice
    Prague, 14000, Czechia
  • Prvni plicni ambulance s.r.o
    Prague, 190 00, Czechia
  • Plicní středisko Teplice s.r.o.
    Teplice, 415 01, Czechia
  • Geo Hospitals Gardabani Multiprofile Medical Centre
    Gardabani, Georgia
  • Geo Hospitals Gurjaani Multiprofile Medical Centre
    Gurjaani, Georgia
  • Geo Hospitals Sagarejo Multiprofile Medical Centre
    Sagarejo, Georgia
  • Medihelp Ltd
    Samtredia, Georgia
  • Imermedi-Imereti Regional Medical Center. (Terjolamedi) Ltd.
    T'erjola, 2400, Georgia
  • Curatio, Jsc
    Tbilisi, 0114, Georgia
  • Geo Hospitals Tbilisi Multiprofile Medical Center
    Tbilisi, 0144, Georgia
  • First Medical Center LLC
    Tbilisi, 0180, Georgia
  • GEO HOSPITALS Zestaphoni Ambulatory Centre
    Zestaponi, Georgia
  • Studienpraxis Berlin-Brandenburg Cornelia Seelbinder Und Lennart Schaper GbR
    Berlin, 10119, Germany
  • Lungenpraxis Hohenzollerndamm
    Berlin, 10717, Germany
  • Klinische Forschung Berlin
    Berlin, 10787, Germany
  • Policum Berlin Studien GmbH Friedenau
    Berlin, 12157, Germany
  • Institut für Allergie- und Asthmaforschung
    Berlin, 12159, Germany
  • Dr. med. Thomas Ginko Facharzt für Lungen- und Bronchialheilkunde
    Bonn, 53119, Germany
  • Neudorfer Lungenpraxis
    Duisburg, 47057, Germany
  • IKF Pneumologie Frankfurt Clinical Research Centre Respiratory Medicine IFS - Interdisziplinäres Facharztzentrum
    Frankfurt, 60596, Germany
  • Athanasios Xanthopoulos Praxis für Pneumologie
    Fürstenwalde, 15517, Germany
  • Praxis für Pneumologie und Allergologie
    Leipzig, 04299, Germany
  • POIS Sachsen GmbH
    Leipzig, 04347, Germany
  • KLB Gesundheitsforschung Lübeck GmbH
    Lübeck, 23552, Germany
  • SMO Zentrum für klinische Studien
    Magdeburg, 39120, Germany
  • Pneumologisches Studienzentrum München
    München, 12159, Germany
  • Siteworks Prüfzentrum Schleswig GmbH
    Schleswig, 24837, Germany
  • Lungenpraxis Witten
    Witten, 58452, Germany
  • "George Papanikolaou" General Hospital of Thessaloniki
    Thessaloniki, 570 10, Greece
  • University of Debrecen, Infectology Clinic Pulmonary unit
    Debrecen, Hungary
  • Erzsébet Gondozóház
    Gödöllő, H-2100, Hungary
  • BKS Research Kft.,
    Hatvan, H-3000, Hungary
  • Revamed Kft
    Nyíregyháza, H-4400, Hungary
  • INFER-MED Kft
    Pécs, Hungary
  • Árkádia Egészségközpont
    Szombathely, H-9700, Hungary
  • Clinica Malattie Respiratorie e allergologia IRCCS Ospedale Policlinico San Martino
    Genova, 16132, Italy
  • University of Messina, Allergy and Clinical Immunology Unit, Department of Experimental and Clinical Medicine
    Messina, 98125, Italy
  • Azienda Ospedaliera dei colli - Ospedale Monaldi
    Naples, 80131, Italy
  • EB FlevoResearch BV
    Almere Stad, 1311 RL, Netherlands
  • Amphia Hospital
    Breda, 4818 CK, Netherlands
  • Gelre Hospitals Zutphen (Gelre ziekenhuizen Zutphen)
    Zutphen, 7207 AE, Netherlands
  • Prywatny gabinet internistyczno-alergologiczny prof. Zenon Siergiejko
    Bialystok, 15-010, Poland
  • Centrum Medycyny Oddechowej, Mróz Spółka Jawna
    Bialystok, 15-044, Poland
  • Uniwersytet Medyczny w Bialymstoku Wydzial Nauk o Zdrowiu Klinika Alergologii i Chorób Wewnetrznych
    Bialystok, 15-276, Poland
  • Prywatna praktyka lekarska. Gabinet pediatryczno - alergologiczny
    Bialystok, 15-430, Poland
  • Vitamed Galaj I Cichomski Sp. J.
    Bydgoszcz, 85-079, Poland
  • Centrum Nowoczesnych Terapii "Dobry Lekarz"
    Krakow, 31-011, Poland
  • Private Health Care MEDYK-KRAK Sp. o.o.
    Krakow, 31-455, Poland
  • Diamond Clinic Spółka z ograniczoną odpowiedzialnością
    Krakow, 31-559, Poland
  • Małopolskie Centrum Alergologii sp. z o.o.
    Krakow, 31-624, Poland
  • ATOPIA Niepubliczny Zakład Opieki Zdrowotnej
    Krakow, 35-159, Poland
  • Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego
    Lodz, 90-153, Poland
  • Makowskie Centrum Medyczne MCM "Hamernia" Maków Podhalański
    Maków Podhalański, 34-220, Poland
  • Ostrowieckie Centrum Medyczne Spółka Cywilna Anna Olech-Cudzik, Krzysztof Cudzik
    Ostrowiec Świętokrzyski, 27-400, Poland
  • Prywatny Gabinet Lekarski Małgorzata Pawlukiewicz
    Rzeszów, 35-051, Poland
  • Clinmedica Research Sp. Z O.O.
    Skierniewice, 96-100, Poland
  • PULMAG Grzegorz Gąsior, Marzena Kociołek spółka cywilna
    Sosnowiec, 41-205, Poland
  • Centrum Medyczne Lucyna i Andrzej DymeK
    Strzelce Opolskie, 47-100, Poland
  • ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z o. o.
    Tarnów, 33-100, Poland
  • CLINICAL BEST SOLUTIONS Fiutkowski Sp. z o.o.
    Warsaw, 41-100, Poland
  • Centrum Badań Klinicznych
    Wroclaw, 51-162, Poland
  • Michał Bogacki Dobrostan
    Wroclaw, 53-301, Poland
  • Lekarze Specjaliści - J. Małolepszy I Partnerzy
    Wroclaw, 54-239, Poland
  • Angisan Grup Srl
    Bragadiru, 769764, Romania
  • Centrul Medical Sana (SANA S.R.L.)
    Bucharest, 011025, Romania
  • National Institute of Pneumology Marius Nasta
    Bucharest, 050159, Romania
  • Medsana Bucharest Medical Center Srl
    Bucharest, Romania
  • Spitalul Clinic de Pneumoftiziologie Leon Daniello
    Cluj-Napoca, 400332, Romania
  • Spitalul Clinic de Pneumoftiziologie Leon Daniello
    Cluj-Napoca, 400394, Romania
  • Spitalul clinic de Pneumoftiziologie Palazu Mare Constanta
    Constanța, 900002, Romania
  • Spitalul Clinic de Boli Infecțioase și Pneumoftiziologie "Victor Babeș" Craiova
    Craiova, 200515, Romania
  • Spital Judetean de Urgenta Bihor
    Oradea, Romania
  • Clinical Hospital of Infectious Diseases and Pneumophysiology Dr.Victor Babeș Timișoara
    Timișoara, Romania
  • Clinical Hospital of Infectious Diseases and Pneumophysiology
    Timișoara, Romania
  • Clinic for Pulmonary Diseases, University Clinical center of Serbia
    Belgrade, 11000, Serbia
  • Municipal Institute for lung diseases and tuberculosis
    Belgrade, Serbia
  • Institute for Pulmonary Diseases of Vojvodina.
    Kamenica, 21204, Serbia
  • Clinic for Pulmonology, University Clinical Center Kragujevac.
    Kragujevac, 34000, Serbia

Showing the first 100 of 118 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Singh D, Mancini L, Melis G, Cortellini M, Rostello C, Mathews KS. Safety and tolerability of the low global warming potential propellant HFA-152a in patients with asthma receiving beclometasone dipropionate/formoterol fumarate/glycopyrronium: The TRECOS study. Respir Med. 2026 May;256:108814. doi: 10.1016/j.rmed.2026.108814. Epub 2026 Apr 6. PubMed 41951188 ↗

Individual participant data

Plan to share: No — Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Feb 2025, 14 months.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 14 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2023
First posted
Feb 20, 2024
StartActual
Nov 27, 2023
Primary completionActual
Feb 18, 2025
CompletionActual
Feb 24, 2025
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06264674
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Nov 27, 2023
Primary completion
Feb 18, 2025
Completion
Feb 24, 2025
Last update
Sep 10, 2026

Study contacts

Dave Singh, MD
principal investigator · Medicines Evaluation Unit, Langley Building, Wythenshawe Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion